Search
VY-HTT01
go.drugbank.com/drugs/DB16999InvestigationalVY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
G207
go.drugbank.com/drugs/DB05827InvestigationalThese viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. … G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG.
Colchiceine
go.drugbank.com/drugs/DB15534ApprovedColchiceine is one of several metabolites of the anti-gout medication [colchicine].[A192714]
Guanosine-5'-Diphosphate
go.drugbank.com/drugs/DB04315ExperimentalA guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem]
RAPA-501-Allo
go.drugbank.com/drugs/DB15890InvestigationalRAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]
LY-517717
go.drugbank.com/drugs/DB05713InvestigationalIt is believed to be Lilly's PMD-3112 (licensed from Amgen).
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVeglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma. … VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma
BMS-986141
go.drugbank.com/drugs/DB14942InvestigationalBMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
Satavaptan
go.drugbank.com/drugs/DB14923InvestigationalSatavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).
7,8-dihydrobiopterin
go.drugbank.com/drugs/DB04400Experimental7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.